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Objectives. Using a decision-analytic model, we sought to
examine the cost-effectiveness of three strategies for cardioversion
of patients admitted to the hospital with atrial fibrillation.
Background. Transesophageal echocardiographic (TEE)-
guided cardioversion has been proposed as a method for early
cardioversion of patients with atrial fibrillation. The cost-
effectiveness of this approach, relative to conventional therapy,
has not been studied.
Methods.We ascertained the cost per quality-adjusted life-year
(QALY) of three strategies: 1) conventional therapy—trans-
thoracic echocardiography (TTE) and warfarin therapy for 1
month before cardioversion; 2) initial TTE, followed by TEE and
early cardioversion if no thrombus is detected; 3) initial TEE, with
early cardioversion if no thrombus is detected. With strategies 2
and 3, if a thrombus is seen, follow-up TEE is performed. If no
thrombus is seen, cardioversion is then performed. All strategies
utilized anticoagulation before and extending for 1 month after
cardioversion. Life expectancy, utilities (quality-of-life weights)
and event probabilities were ascertained from published reports.
Cost estimates were based on published data and hospital ac-
counting information.
Results. Transesophageal echocardiographic-guided early car-
dioversion (strategy 3: cost $2,774, QALY 8.49) dominates TTE/
TEE-guided cardioversion (strategy 2: cost $3,106, QALY 8.48)
and conventional therapy (strategy 1: cost $3,070, QALY 8.48)
because it is the least costly with similar effectiveness. Sensitivity
analyses demonstrated that TEE-guided cardioversion (strategy
3) dominates conventional therapy if the risk of stroke after TEE
negative for atrial thrombus is slightly less than that after
conventional therapy (baseline estimate 0.8%). The results also
depend on the risk of major hemorrhage but are less sensitive to
baseline estimates of morbidity from TEE, cost of TTE, cost of
hospital admission for cardioversion and utilities for health
states.
Conclusions. On the basis of a decision-analytic model, TEE-
guided early cardioversion, without TTE, is a reasonable cost-
saving alternative to conventional therapy for patients admitted to
the hospital with atrial fibrillation. Such a strategy appears
particularly beneficial for patients with an increased risk of
hemorrhagic complications. Future clinical studies examining the
TEE strategy should consider eliminating initial TTE and care-
fully assess both the thromboembolic and hemorrhagic risk.
(J Am Coll Cardiol 1997;29:122–30)
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Atrial fibrillation is the most common sustained arrhythmia,
resulting in .179,000 hospital admissions in 1990 alone (1).
The resultant loss of atrial mechanical function and associated
blood stasis increases the risk of atrial thrombus formation and
thromboembolism. Restoration of sinus rhythm relieves symp-
toms, improves hemodynamic variables and may lower throm-
boembolic risk. The likelihood of restoring sinus rhythm and
the recovery of atrial systolic function are both inversely
related to the duration of atrial fibrillation before cardiover-
sion (2,3). Furthermore, the longer the course of anticoagula-
tion, the greater the risk of hemorrhage. Therefore, it would be
desirable to convert atrial fibrillation to sinus rhythm as early
as possible.
Because transthoracic echocardiography (TTE) is not reli-
able for excluding left atrial thrombi (4–6), conventional
therapy for patients presenting with atrial fibrillation .48 h in
duration includes 3 to 4 weeks of warfarin therapy before
cardioversion (7). Cardioversion in the absence of anticoagu-
lation results in clinical thromboembolism in 5% to 7% of
patients (8–11). Although no randomized trials have been
reported, 3 to 4 weeks of warfarin therapy decreases the risk of
cardioversion-related thromboembolism to 0% to 1.6% (8–
11). One month of warfarin therapy is also prescribed after
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cardioversion for prophylaxis during recovery of atrial mechan-
ical function (3) and to prevent reversion to atrial fibrillation.
The downside of conventional therapy includes hemorrhagic
complications associated with warfarin (10,12–17), increased
use of outpatient services for monitoring, a delay in cardiover-
sion for the majority of patients who would not experience
thromboembolism and the need for a brief second hospital stay
(or day visit) for cardioversion.
Transesophageal echocardiography (TEE) offers superior
visualization of the left atrium and its appendage (4–6,18) and
thus offers the opportunity to perform early cardioversion if
TEE results are negative for atrial thrombus (19–24). How-
ever, patients without evidence of atrial thrombi on TEE may
still be at risk for embolization after cardioversion (25–28).
Moreover, TEE does have associated morbidity and mortality
(28–30), and the relative cost-effectiveness of a TEE-guided
strategy for early cardioversion compared with conventional
therapy has yet to be determined. Because patients who are
admitted to the hospital for evaluation and initial therapy for
atrial fibrillation (rate control, initiation of intravenous and
oral anticoagulation) may benefit the most from a TEE-guided
approach, we sought to examine the efficacy and cost-
effectiveness of these treatment options using a decision-
analytic approach.
Methods
Decision model. On the basis of the average age and
gender of patients enrolled in recent studies of cardioversion
for atrial fibrillation (19–24), we constructed a decision model
(Fig. 1) for a prototypic 70-year old patient who is admitted to
the hospital for initial treatment of atrial fibrillation.2 days in
duration and for whom elective cardioversion is desired. The
model does not pertain to patients with atrial fibrillation not
admitted to the hospital or to those who spontaneously revert
to sinus rhythm. The time frame of the model is 2 months—
from index hospital admission through 1 month after elective
cardioversion. Survival after 2 months was modeled using the
Declining Exponential Approximation of Life Expectancy
(DEALE) method (29–31). We used SMLTREE software (32)
to compare the incremental cost-effectiveness of three strate-
gies.
Strategy 1: conventional therapy. After hospital admission,
intravenous heparin and oral warfarin therapy is started, and a
TTE is performed to evaluate left atrial size and severity of
mitral regurgitation, to exclude occult mitral stenosis and to
assess left ventricular systolic function (33). Because TTE
cannot reliably exclude a left atrial thrombus (4–6,19), once
Abbreviations and Acronyms
ACUTE 5 Assessment of Cardioversion
Using Transesophageal
Echocardiography
CPT 5 current procedural terminology
DC 5 direct cardioversion
DEALE 5 Declining Exponential
Approximation of Life Expectancy
QALY 5 quality-adjusted life-year
TEE 5 transesophageal echocardiography,
transesophageal echocardiographic
TTE 5 transthoracic echocardiography
Figure 1. Decision tree model. Ini-
tial treatment strategy decision for
patients with atrial fibrillation (sol-
id square at left) and chance events
(solid circles). Patients who un-
dergo TEE have a risk of esopha-
geal perforation and, if they sur-
vive, are assumed to remain in
atrial fibrillation. Patients with left
atrial clot detected receive antico-
agulation for 4 weeks and return
for follow-up TEE. If a left atrial
clot is detected on follow-up TEE,
then patients do not undergo car-
dioversion and remain in atrial fi-
brillation. Patients with no left
atrial clot detected on follow-up
TEE (asterisk) follow the same
course as patients without left
atrial clot detected on initial TEE.
Not represented is the 4 weeks of
anticoagulation after cardiover-
sion. Boxes represent outcomes in
terms of costs ($) and QALYs.
LA 5 left atrial; perforation 5
esophageal perforation related to
TEE.
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warfarin anticoagulation is therapeutic, the patient is dis-
charged in atrial fibrillation for an additional 1 month of
outpatient warfarin therapy before elective cardioversion;
anticoagulation has an attendant risk of major hemorrhage.
During a second brief hospital stay or day visit, the patient
undergoes elective cardioversion (pharmacologic or direct
current), with an associated risk of neurologic impairment or
death due to cardioversion-related thromboembolism. Patients
who did not have a hemorrhagic complication receive an
additional 1 month of warfarin therapy after cardioversion as
prophylaxis against thrombus formation during the recovery of
atrial mechanical function and in case of recurrent atrial
fibrillation (3,7,24,34–36), with attendant cost and morbidity.
Strategy 2: TEE-guided cardioversion with TTE. After hos-
pital admission, intravenous heparin and oral warfarin therapy
is started, and TTE is performed. If TTE does not detect an
atrial thrombus, TEE is performed within 24 h of admission,
with possible associated morbidity. If no thrombus is detected
by either study, cardioversion is performed within 24 h with an
attendant risk of neurologic impairment or death due to
cardioversion-related thromboembolism. If a thrombus is de-
tected by either TTE or TEE, the patient receives 4 weeks of
warfarin therapy, and follow-up TEE is performed at 1 month,
followed by cardioversion if no thrombus is seen. However, if
the thrombus persists, the patient remains in atrial fibrillation
and continues warfarin therapy. All patients receive 1 month of
outpatient anticoagulation after cardioversion, with an atten-
dant cost and morbidity.
Strategy 3: TEE-guided cardioversion. After hospital admis-
sion, intravenous heparin and oral warfarin therapy is started,
and TEE is performed within 24 h. If no thrombus is detected,
cardioversion is performed within 24 h, with the risk of
neurologic impairment or death due to cardioversion-related
thromboembolism. If a thrombus is seen by TEE, the patient
receives 4 weeks of warfarin therapy and follow-up TEE is
performed at 1 month followed by cardioversion if no throm-
bus is seen. If the thrombus persists, then the patient remains
in atrial fibrillation and continues warfarin therapy. All pa-
tients receive 1 month of outpatient anticoagulation after
cardioversion with attendant cost and morbidity.
Assumptions. We made several simplifying assumptions in
the analysis.
Anticoagulation and hemorrhage. 1) All patients receive
anticoagulation from the time of admission through 1 month
after cardioversion. Those with a hemorrhage before cardio-
version have their anticoagulant therapy stopped and remain
in atrial fibrillation for the observation period. 2) The only
complication of warfarin therapy considered is major hemor-
rhage, defined as a hemorrhage that requires a transfusion or
that is life-threatening and requires hospital admission. Cost
and morbidity related to non-major hemorrhagic complica-
tions are not considered. This assumption favors conventional
therapy (strategy 1) because patients in that strategy receive
warfarin for twice as long as others, and thus their risk of a
non-major hemorrhagic complication would be expected to be
higher. 3) For patients in strategy 1, cardioversion is attempted
after 1 month of warfarin therapy for all patients. This
assumption favors conventional therapy (strategy 1) because
data suggest that 25% of patients scheduled for cardioversion
of atrial fibrillation after 1 month of warfarin have cardiover-
sion delayed due to inadequate anticoagulation or hemor-
rhagic complications (24).
Cardioversion. 1) Patients undergoing conventional ther-
apy (strategy 1) undergo initial TTE to evaluate left atrial size,
ascertain the presence and severity of mitral regurgitation,
exclude occult mitral stenosis and assess left ventricular systolic
function (33). Because patients in clinical practice might not
undergo initial TTE as part of their management, we per-
formed a sensitivity analysis comparing TEE-guided cardiover-
sion (strategy 3) versus conventional therapy without initial
TTE (i.e., anticoagulation and cardioversion without echocar-
diography). 2) All cardioversions are successful in restoring
sinus rhythm, and sinus rhythm is maintained at equal rates
under all strategies. This assumption favors conventional ther-
apy (strategy 1) because patients who undergo TEE-guided
early cardioversion (strategies 2 and 3) have a shorter (by 1
month) duration of atrial fibrillation before cardioversion and
thus have a more rapid recovery of atrial mechanical function
(3) and a greater chance of maintaining sinus rhythm (3). 3)
The only morbidity from cardioversion considered is cerebral
embolism/stroke. 4) Patients with esophageal perforation or a
persistent thrombus detected on follow-up TEE (after 4 weeks
of anticoagulation) do not undergo cardioversion and are
assumed to remain in atrial fibrillation. This assumption favors
conventional therapy (strategy 1) because we assumed that
patients who remained in atrial fibrillation had a shorter life
expectancy than those in sinus rhythm. 5) After 4 weeks of
warfarin therapy for an atrial thrombus, a patient who has
repeat TEE showing no atrial thrombus has the same risk of
cardioversion-related clinical thromboembolization as a pa-
tient who did not have a thrombus seen on the initial study. 6)
All cardioversions are elective.
Cost. 1) All patients are initially admitted to the hospital
for 3 nights, corresponding to Diagnostic Related Group
(DRG) 139-Cardiac Arrhythmia and Conduction Disorders
without Complication, which allows an average length of stay
of 3.3 nights (37). While in the hospital, the patient typically
undergoes evaluation and treatment to control the ventricular
rate, anticoagulation with heparin and warfarin, echocardiog-
raphy and cardioversion (for strategies 2 and 3). Elective
cardioversion after 4 weeks of warfarin therapy for patients
undergoing conventional therapy (strategy 1) and for patients
with evidence of thrombi on TEE requires a 1-day hospital stay
or day visit. Because some physicians may choose to perform
this elective cardioversion on an outpatient basis, we varied the
cost of this second hospital visit to determine its effect on the
analysis. 2) The cost of death from esophageal perforation is
the same as that for death from major hemorrhage.
Risk of TEE. 1) The only major complication of TEE is
esophageal perforation. Other complications, such as arrhyth-
mias, hypoxia and hoarseness are transient (24,38–40), and
thus were not considered in our baseline analysis. In our
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sensitivity analysis, we varied the major complication rate of
TEE over a wide range to account indirectly for these other
complications.
Probabilities. Event probabilities were ascertained from
published reports and are summarized in Table 1.
Risks of hemorrhage. Published estimates of the risk of
hemorrhage associated with anticoagulation vary widely. Re-
cent large, prospective, multicenter clinical trials of warfarin
for nonvalvular atrial fibrillation (12–17) found major hemor-
rhage rates of 0.8% to 2.5%/year. For our baseline analysis, we
selected the midpoint of this range, 1.7%/year, as the major
hemorrhage rate.
On the basis of evidence that the risk of major hemorrhage
from anticoagulation is greatest during the initial month of
therapy (41–43), we estimated that the risk of major bleeding
was three times greater during the first month of therapy
compared with subsequent months. Thus, our baseline esti-
mates for the rate of major hemorrhage were 0.36% for those
receiving 1 month of warfarin therapy (strategy 2 and 3) and
0.48% for those receiving 2 months of warfarin therapy
(strategy 1). This assumption favors conventional therapy
(strategy 1) because the monthly risk of hemorrhage during the
second month was estimated to be lower than the first. Our
baseline estimate is much lower than the 1-month major
hemorrhage rate of 1.6% reported in a recent population-
based study of anticoagulant therapy (41). Our estimate is also
conservative with respect to the 2-month hemorrhagic compli-
cation rate of 1.6% among patients in the Assessment of
Cardioversion Using Transesophageal Echocardiography
(ACUTE) pilot study randomized to strategy 1 (24).
Of patients with a major hemorrhage, we estimated that 6%
die, 2% have long-term morbidity, and 92% recover after a
short hospital stay (44).
Probability of detecting a left atrial thrombus by TTE or TEE.
The true sensitivity and specificity of TTE and TEE in
detecting left atrial thrombi in patients with atrial fibrillation
are unknown. Rather than estimating this directly, we esti-
mated the probability that a patient with new atrial fibrillation
will have a thrombus detected by TTE or TEE. On the basis of
published data, our baseline analysis assumes that, of patients
presenting with new atrial fibrillation, TTE detects thrombi in
2%, TEE detects thrombi in 15%, and among those with a
negative TTE, TEE detects thrombi in 14% (21–23). The
probability of seeing a persistant thrombus by TEE on the
follow-up examination at 1 month was estimated at 15% (45).
Probability of stroke after cardioversion. Several retrospec-
tive studies (9–11) and one nonrandomized, prospective study
(8) of elective cardioversion have shown an incidence of
cardioversion-related thromboembolism of 0% to 1.6% for
patients receiving warfarin for 2 to 4 weeks before cardiover-
sion (strategy 1) (8–11). On the basis of these data, we
assumed a baseline risk of stroke of 0.8% after 1 month of
anticoagulation. For the risk of stroke after cardioversion
among patients without evidence of atrial thrombi on TEE, we
assumed a baseline risk of 0.5% (or relative risk of 0.625
[5 0.5/0.8]) based on the approximate midpoint of the 95%
confidence interval from prospective data gathered from three
trials (n5 340) utilizing a protocol similar to strategy 2 (22–24)
(combined stroke rate 0%, 95% confidence interval 0% to
0.9%). Because the stroke rates after TEE-guided cardiover-
sion and conventional therapy are not firmly established, we
linked them to each other (ratio) to examine how the relative
risk of stroke after TEE-guided cardioversion versus conven-
tional therapy affected the cost-effectiveness ratio. Of those
with clinical cerebral embolization, we estimated that 24% die,
30% have long-term morbidity, and 46% have only a minor
stroke with full recovery (44).
In our analysis, patients with major hemorrhagic complica-
tions before cardioversion remain in atrial fibrillation and do
not take warfarin. Because such patients are at an increased
risk of thromboembolism, we assumed an embolic risk of
4.3%/year (0.004%/month) based on data from randomized
trials of warfarin versus placebo for patients in atrial fibrilla-
tion (12–17). In our baseline model, patients with a thrombus
detected on initial echocardiography and repeat TEE after 4
weeks of warfarin do not undergo cardioversion and therefore
remain in atrial fibrillation. Because these patients might have
a higher embolic risk than patients without a thrombus de-
tected on TEE, they were given an additional stroke risk of
0.05% during the observation period.
Risks of TEE. Life-threatening complications associated
with TEE are rare. In a review of 10,419 examinations, Daniel
Table 1. Baseline Probability Estimates
Variable
Baseline
(%)
Reference
No.
Hemorrhage in pts taking warfarin
Annual rate 1.7 12–17
1st-mo rate 0.36 41–43
2nd-mo rate 0.12 41–43
Thrombus detected in pts with AF
By TTE 2 23
By TEE 15 23
By TEE if none seen on TTE 14 23
By TEE after 4 wk of anticoagulation
if thrombus detected on initial
TTE or TEE
15 45
Complications from hemorrhage
None 92 44
Long-term morbidity 2 44
Death 6 44
Stroke after cardioversion
After 4 wk of anticoagulation (strategy 1) 0.8 8–11
If no thrombus detected by TEE
(strategies 2 and 3)
0.5 22–24
Neurologic sequelae of stroke
Minor 46 44
Long-term morbidity 30 44
Death 24 44
Esophageal perforation
Incidence 0.02 46, 47
Mortality 8.0 48
AF 5 atrial fibrillation; pts 5 patients; TEE 5 transesophageal echocardi-
ography; TTE 5 transthoracic echocardiography.
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et al. (38) reported only one death (0.0098%), which was
caused by laceration of a malignant lung tumor penetrating
into a patient’s esophagus. Other complications, such as bron-
chospasm, arrhythmias and hoarseness, are rare and transient
(38–40). Chan et al. (34) reviewed 1,500 consecutive TEE
examinations and reported no deaths. Reversible complica-
tions, such as stridor, wheezing or transient, asymptomatic
atrial fibrillation, occurred in five (0.3%) patients (39). In a
preliminary report, the Value of Transesophageal Echocardi-
ography (VOTE) study (40) also reported no deaths among
3,003 examinations. Esophageal perforation is the most seri-
ous, life-threatening complication of TEE. The risk of esoph-
ageal perforation for diagnostic endoscopy ranges from 0.01%
to 0.03% (46,47). These data most likely overestimate the risk
of perforation during TEE because patients in the endoscopic
studies had esophageal disease. To be conservative, we as-
sumed a baseline risk of esophageal perforation of 0.02% and
also assumed that patients who experienced esophageal perfo-
ration would not undergo cardioversion. The mortality rate
from esophageal perforation related to diagnostic endoscopy
has been estimated to be 8.0% (48), which is the rate we used
in our analysis.
Effectiveness. Effectiveness was measured in terms of
quality-adjusted life-years (QALYs), which was calculated for
each outcome by multiplying the life expectancy by its utility
(quality of life weight ranging from 0 to 1). For patients
surviving the 2-month time horizon, we first estimated the
expected mortality rate as the sum of the age-adjusted annual
mortality rate plus the disease-specific mortality rate and then
calculated life expectancy by taking the reciprocal of the
overall mortality rate, according to the DEALE method (29–
31).
The baseline annual mortality rate for a 70-year old person
is 0.072 (49). The annual disease-specific mortality rate due to
major stroke and major hemorrhage has been estimated to be
0.49 and 0.52, respectively (44,50). In addition, due to the
possible recurrence of atrial fibrillation after cardioversion, we
estimated the disease-specific postcardioversion mortality rate
to be 0.016 (50). Thus, the annual disease-specific mortality
rate of patients in chronic atrial fibrillation was estimated to be
0.027 for patients receiving long-term warfarin therapy and
0.043 for those not receiving anticoagulation (12–16).
Because patients with esophageal perforation do not un-
dergo cardioversion and do not receive anticoagulation, these
patients were assigned the disease-specific mortality rate of
those with chronic atrial fibrillation, 0.043 (12–16). Thus, for
example, the expected mortality rate of a 70-year old man with
a major stroke is 0.562 (5 0.072 1 0.49), and the life
expectancy is 1.78 (5 1/0.562) years.
The utility of death was set at 0.0 and that of successful
cardioversion without stroke or major hemorrhage (using any
strategy) equal to 1.0. Utility estimates for embolization and
hemorrhage were based on published data (44). The utility
resulting from stroke with long-term morbidity was assumed to
be 0.5, whereas that of minor stroke was assumed to be 0.7 for
the first month only (44). For hemorrhage, the utility associ-
ated with long-term morbidity was 0.6, whereas that of hem-
orrhage without long-term morbidity was 0.9 for 1 month (44).
The utility of esophageal perforation was assumed to be the
same as that for major hemorrhage with resolution. If more
than one condition was present, the lowest utility was used. All
life-years were discounted at 5%.
Costs. Because hospital and physician charges may not
reflect true economic costs (51), we used costs rather than
charges and based our estimates on both published data and
actual cost estimates at our institution (Table 2) in 1993. For
costs of hemorrhagic complications and stroke, including the
cost of hospital admission and long-term care, we used the
variable cost estimates of Eckman et al. (44). The variable
costs of esophageal perforation, hospital admission for atrial
fibrillation and elective cardioversion were obtained from our
hospital cost accounting information.
We estimated the cost of a month of warfarin therapy using
the wholesale cost of 4 mg/day of warfarin and the laboratory
cost of four prothrombin time tests (the rate charged to
institutions by a private laboratory in Boston). No cost was
assumed for physician/nurse interpretation and management
of warfarin therapy. This would favor strategy 1 (conventional
therapy) because more prothrombin time assessments are
made under that strategy. To obtain the physician costs for
performing and interpreting echocardiography, we converted
the current procedural terminology (CPT) codes (52,53) for
TTE (CPT code 93307) and TEE (CPT code 93312) into
resource-based relative value units (RBRVUs) and then used
the Medicare reimbursement rate to convert these into dollars
(54). The remainder of the TTE and TEE costs included
technician fees, probe depreciation and equipment mainte-
Table 2. Costs and Utilities
Variable
Baseline
Cost ($) Source
Echocardiography
TTE 321 Hospital accounting and
TEE 432 Medicare reimbursement
Embolization after cardioversion
Minor stroke 4,438 Eckman et al. (44)
Major stroke 22,939 Eckman et al. (44)
Death due to stroke 5,980 Eckman et al. (44)
Complication of TEE
Esophageal perforation 1,602 Hospital accounting
Death due to perforation 5,980 *
Hemorrhage
No morbidity 3,172 Eckman et al. (44)
Morbidity 24,546 Eckman et al. (44)
Anticoagulation/mo
Warfarin therapy (4 mg/day) 15 Wholesale cost
Prothrombin time test (1/wk) 42 Wholesale cost
Hospital stay
Initial stay 1,856 Hospital accounting
Second stay 464 Hospital accounting
Elective cardioversion 213 Hospital accounting
*Assumed to be the same as death due to stroke.
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nance. We subsequently varied the cost of TEE in our sensi-
tivity analysis.
Costs were discounted at 5%/year, and future outpatient
costs were obtained by summing annual discounted outpatient
costs over the predicted life expectancy (44). All costs are
expressed in 1993 dollars, with costs from previous years
inflated using the medical care component of the consumer
price index.
Sensitivity analysis. We performed sensitivity analyses by
varying the baseline probabilities, utilities and costs over wide
ranges. We also performed threshold analyses to identify
values for model variables that would result in an incremental
cost-effectiveness ratio.$50,000/QALY, an often cited thresh-
old for cost-effective care (55–57).
Results
Baseline analysis. Using our baseline assumptions, the cost
and QALYs for each strategy are summarized in Table 3.
TEE-guided cardioversion (strategy 3) is the least costly strat-
egy ($2,774) compared with $3,070 for conventional therapy
(strategy 1) and $3,106 for TTE/TEE-guided cardioversion
(strategy 2). There is no meaningful difference in effectiveness
between the three strategies (Table 3). Thus, TEE-guided
cardioversion (strategy 3) dominates in that it is the least costly
with similar effectiveness.
Sensitivity analyses. Most centers that use TEE to guide
cardioversion of atrial fibrillation have followed a TTE/TEE-
guided cardioversion strategy (20–24) (strategy 2). In our
sensitivity analyses, this strategy is always dominated by TEE-
guided cardioversion (strategy 3) because strategy 2 has the
additional cost of TTE without added measurable effectiveness
for guiding early cardioversion. Thus, our sensitivity analyses
focus on comparing TEE-guided early cardioversion (strategy
3) with conventional therapy (strategy 1).
Probability of thromboembolism. We varied the relative
risk of stroke (ratio of stroke risk after TEE-guided cardiover-
sion to the stroke risk after conventional therapy) to analyze
how the probability of thromboembolism affects the incremen-
tal cost-effectiveness of TEE-guided cardioversion (strategy 3)
compared with conventional therapy (strategy 1). If the rela-
tive risk of stroke using TEE-guided cardioversion is ,0.95,
TEE-guided cardioversion is both more effective and less
costly than conventional therapy. At a relative risk .0.95,
TEE-guided cardioversion remains less costly but is also less
effective. At a relative risk of 1.1, the incremental cost-
effectiveness for TEE-guided cardioversion is $50,000/QALY.
In our analysis, we assumed that patients with a thrombus
detected on follow-up TEE after 4 weeks of anticoagulation
would not undergo cardioversion. Because such patients may
have a higher risk of embolism than those without a thrombus,
their risk of embolism was increased by 0.05%. TEE-guided
cardioversion is still less costly and more effective than con-
ventional therapy if this added risk of stroke were as high as
13%.
Probability of hemorrhage. We varied the risk of major
hemorrhage from its baseline of 1.7%/year (0.36% first-month
risk) while varying the relative risk of postcardioversion stroke
(risk of postcardioversion stroke with strategy 3 vs. strategy 1)
from 0 to 1.25 (Fig. 2). Assuming that the risk of hemorrhage
during the first month of anticoagulation is three times as great
as that in the subsequent month (42), we varied the annual risk
of hemorrhage from 0.8%/year (0.2% first-month risk) to
11%/year (2.4% first-month risk). Using the 0.8%/year risk of
hemorrhagic complication, TEE-guided cardioversion (strate-
gy 3) remains more effective than conventional therapy (strat-
egy 1) if the relative risk of postcardioversion stroke is ,0.56.
If the relative risk of stroke after TEE-guided cardioversion is
.4.7, then conventional therapy is more effective, even at a
risk of hemorrhage as high as 11%/year (2.4% first-month
risk).
Complications of TEE. The reported risk of esophageal
perforation for diagnostic endoscopy ranges from 0.01% to
0.03% (24,46,47). Within this range, TEE-guided cardiover-
sion (strategy 3) dominates conventional therapy (strategy 1).
To estimate how a higher overall complication rate of TEE
might affect our results, we varied the risk of perforation to
find the value at which TEE-guided cardioversion becomes less
effective than conventional therapy. The risk of TEE-related
esophageal perforation would have to be .0.30% before
conventional therapy is more effective than TEE-guided car-
dioversion.
Costs and utilities. Holding the cost of TTE at its baseline
of $321, we varied the cost of TEE. If the cost of TEE increases
to $1,100, the incremental cost-effectiveness of TEE-guided
cardioversion (strategy 3) compared with conventional therapy
(strategy 1) is $50,000/QALY.
In the model, all patients undergoing conventional therapy
(strategy 1) return after 1 month of warfarin therapy for a
1-day hospital stay for elective cardioversion, as do patients
Table 3. Baseline Results
Strategy Cost ($) QALY
Incremental
Cost-Effectiveness
TEE-guided cardioversion (strategy 3) 2,774 8.49 —
Conventional therapy (strategy 1) 3,070 8.48 Dominated
TEE-guided cardioversion with TTE (strategy 2) 3,106 8.48 Dominated
Dominated 5 more costly and less effective than transesophageal echocardiographic (TEE)-guided cardioversion;
QALY 5 quality-adjusted life-year; TTE 5 transthoracic echocardiography.
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who had a thrombus detected by initial TEE. Because some
physicians may elect to perform cardioversion on an outpatient
basis, we varied the cost of this second hospital stay. Even if
there were no cost for this elective hospital stay, TEE-guided
cardioversion (strategy 3) costs only $110 more than conven-
tional therapy ($2,718 vs. $2,608) and remains slightly more
effective, with an incremental cost-effectiveness of $11,512/
QALY.
The results are insensitive to both the cost of esophageal
perforation and the cost of death due to esophageal perfora-
tion. For the TEE strategy not to dominate, the cost of
perforation (or other complications with similar mortality)
would have to exceed $1.2 million, or the cost of death due to
perforation would have to exceed $13 million.
Our results were not significantly affected when utilities for
major stroke, hemorrhage with long-term morbidity and
esophageal perforation were varied individually over wide
ranges.
Alternative strategy: conventional therapy without TTE.
The initial TTE as part of conventional therapy (strategy 1) has
little impact on the decision-making process but does have
associated cost. We thus compared TEE-guided cardioversion
(strategy 3) with a strategy similar to conventional therapy but
without the initial TTE. If the initial TTE were eliminated
from conventional therapy, TEE-guided cardioversion is
slightly more expensive than conventional therapy ($2,774 vs.
$2,750) but remains more effective, with an incremental cost-
effectiveness of $2,539/QALY.
Discussion
In this decision analysis, we examined three clinical strate-
gies for guiding cardioversion of patients admitted to the
hospital with new atrial fibrillation. Using our baseline assump-
tions, TEE-guided cardioversion without initial TTE (strategy
3) is identified as an effective and cost-saving alternative to
conventional therapy (strategy 1). In our sensitivity analysis we
found that the results are dependent on the risk of postcardio-
version stroke in TEE-negative patients being slightly lower
than the risk of stroke after conventional therapy. Although
several case reports or small series have reported thromboem-
bolism after TEE-guided cardioversion in the absence of
anticoagulation (25–28), three prospective trials, involving
.340 patients and using an anticoagulation schedule similar to
strategy 3, have reported a stroke rate of 0% (95% confidence
interval 0% to 0.9%) (22–24). The importance of adequate
anticoagulation from the time of TEE through 1 month after
cardioversion is underscored by data demonstrating more
pronounced atrial spontaneous contrast—a marker of stasis
(58,59)—as well as new thrombus formation immediately after
cardioversion (60).
The cost-effectiveness of TEE-guided cardioversion (strat-
egy 3) is sensitive to the risk of major hemorrhage. Our
baseline annual hemorrhage rate estimate was derived from
data gathered from five large multicenter, prospective studies
of warfarin therapy in patients with atrial fibrillation (12–17).
This estimate most likely underestimates the true risk of
hemorrhage in clinical practice for patients admitted to the
hospital with atrial fibrillation because these long-term studies
excluded many patients who might be considered candidates
for short-term anticoagulation. Observational studies of war-
farin therapy have noted a major hemorrhage rate of 0.6% to
7.4%/year (41,61–63). The discrepancy with the previously
mentioned multicenter trials of long-term warfarin therapy for
atrial fibrillation is most likely related to the exclusion of 60%
to 90% of potential enrollees in the nonvalvular atrial fibrilla-
tion trials (15,16), including those patients with a higher
propensity to bleed (64). Data from the ACUTE pilot study
(24) demonstrated major hemorrhage rates of 1.6% during 2
months of observation for patients receiving conventional
therapy and 0% for patients undergoing TTE/TEE-guided
cardioversion. In addition, the ACUTE pilot study found that
almost 25% of patients randomized to conventional therapy
(strategy 1) did not undergo cardioversion after 1 month (as
intended) due to transiently subtherapeutic anticoagulation.
For those patients, cardioversion was delayed, and the actual
duration of anticoagulation was extended, again suggesting
that our baseline estimates for hemorrhagic complications
were conservative. Although we did not formally include the
possibility of subtherapeutic anticoagulation in the model, a
prolonged course of warfarin for the conventional group
Figure 2. Two-way sensitivity analysis: relative risk of stroke after
cardioversion versus risk of hemorrhage during the first month of
warfarin therapy. The relative risk of stroke after cardioversion is
plotted against the risk of hemorrhage during the first month of
warfarin therapy, which varied from 0.2% (0.8%/year) to 2.4% (11%/
year). The relative risk of stroke is the ratio of the risk after
TEE-guided cardioversion (strategy 3) to the stroke risk after conven-
tional therapy (strategy 1). Solid line represents the values at which the
effectiveness of TEE-guided cardioversion (strategy 3) and conven-
tional therapy (strategy 1) are equivalent. Values above the line favor
conventional therapy, and values below the line favor TEE-guided
cardioversion. If the relative risk of postcardioversion stroke is ,0.56,
then TEE-guided cardioversion (strategy 3) is more effective than
conventional therapy, even if the risk of first-month hemorrhage is as
low as 0.2%. If the relative risk of stroke after cardioversion is .4.7,
then conventional therapy is more effective, even with a first-month
hemorrhage risk as high as 2.4%. Asterisk represents baseline esti-
mates of hemorrhage risk (0.32%) and relative risk of stroke (0.625).
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(strategy 1) would expose them to a higher risk of hemorrhagic
complication.
Study limitations. Our analysis assumes that the duration
of the initial hospital period is similar for all strategies, that
TEE is performed by an experienced physician and that
cardioversion is performed expeditiously (while the patient is
receiving heparin and the prothrombin time is advancing
toward therapeutic range). Our results are not generalizable to
patients who are managed exclusively as outpatients. Our
model also does not account for potential cost savings from
patients treated in a conventional manner who spontaneously
convert while awaiting elective cardioversion. Finally, we as-
sumed that the initial TTE in the conventional therapy strategy
provided no additional information to influence the decision to
perform or withhold cardioversion. Because TTE is generally
performed to exclude occult mitral stenosis, evaluate left atrial
size and left ventricular function and assess the presence and
severity of mitral regurgitation, we may have underestimated
its clinical role in guiding the decision to perform cardiover-
sion.
Conclusions. Our analysis demonstrates that TEE-guided
early cardioversion, without initial TTE, is a reasonable and
potentially cost-saving alternative to present-day conventional
therapy for patients admitted to the hospital with new atrial
fibrillation. Sensitivity analysis demonstrated that these con-
clusions are dependent on the risk of cardioversion-related
thromboembolism after negative TEE being slightly lower than
the risk associated with conventional therapy. By avoiding 1
month of anticoagulation, the TEE approach also appears
particularly beneficial for those with an increased risk of
hemorrhagic complications. Further studies examining the role
of TEE in this population should consider eliminating the
initial TTE in patients eligible for TEE-guided cardioversion,
with careful assessment of hemorrhagic risk.
We wish to thank James P. Morgan, MD, PhD, David J. Cohen, MD and Allan
Klein, MD for their helpful review of the manuscript.
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